Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma

Next Previous
Trial Profile

A Phase 2, Multicenter, Open-label, Proof-of-concept Study With Safety Run-in to Evaluate the Safety, Pharmacokinetics, and Efficacy of VP-315 in Adult Subjects With Basal Cell Carcinoma

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 14 Oct 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ruxotemitide (Primary)
  • Indications Basal cell cancer
  • Focus Adverse reactions; Proof of concept; Registrational; Therapeutic Use
  • Sponsors Verrica Pharmaceuticals

Most Recent Events

  • 12 Aug 2025 According to Verrica Pharmaceuticals media release, following End-of-Phase 2 meeting with the FDA, company now have additional clarity and broad agreement on advancing the therapy into a pivotal Phase 3 program and preparation activities are underway.
  • 14 May 2025 According to a Lytix Biopharma media release, company expects to announce additional genomic and immune response data for VP-315 in mid-2025.
  • 13 Feb 2025 According to a Lytix Biopharma media release, company is preparing for FDA discussions in H1 2025 to outline the path toward a Phase III trial.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top